Fabry disease: We have extended our basic investigations on enzyme replacement therapy (ERT) and gene therapy (GT) for this hereditary metabolic disorder using the alpha-galactosidase A (alpha-Gal A) knock-out animal model of Fabry disease created by the Developmental and Metabolic Neurology Branch. Intravenous administration of purified alpha-Gal A reduced the toxic accumulations of globotriaosylceramide (Gb3) in many organs of the mice. It restored the prolonged QRS complex to normal, and it reversed the abnormal permeability of kidney glomeruli to albumin. Current experiments are directed to evaluation of ERT on the increased susceptibility of blood vessels to the damaging effects of Gb3. It is anticipated that this information will be of great value in developing treatment strategies for patients with Fabry disease who are particularly susceptible to premature strokes and heart attacks. We have extended our investigations on gene therapy for Fabry disease using the knock-out murine model. Two notable accomplishments occurred in the past year. We found that injection of an adeno-associated virus (AAV) vector containing the alpha-Gal A gene into the hepatic portal vein caused long-term enzymatic and functional correction in multiple organs of the mice. Following the administration of this vector, reduction of Gb3 in the liver, spleen and heart lasted more than 25 weeks. There were no signs of toxicity to AAV. In another investigation, we developed a procedure to preselect stem and progenitor cells that had been transduced with the alpha-Gal A gene. To accomplish this goal, we prepared a biscistronic retroviral vector containing the alpha-Gal A gene as well as the human IL-2Ra chain (huCD25) as the selectable marker. This preselection technique greatly increased the level of multilineage gene-corrected hematopoietic cells in transplanted mice, and it increased the amount of alpha-Gal A activity in the plasma and organs of the transplanted animals. These investigations provide further support of the potential of gene therapy for Fabry disease. Mucolipidosis IV: We reported last year that we discovered the gene that is mutated in patients with this devastating neurogenetic disorder. The product of the gene has been identified as a 580 amino acid protein called mucolipin. We are investigating the function of mucolipin in vitro and in cell cultures. We are preparing antibodies to mucolipin to assist in determining its subcellular localization. Moreover, we are developing models of the disorder in Drosophila and in mice.
| Shin, Sang H; Kluepfel-Stahl, Stefanie; Cooney, Adele M et al. (2008) Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics 18:773-80 |
| Goldin, Ehud; Caruso, Rafael C; Benko, William et al. (2008) Isolated ocular disease is associated with decreased mucolipin-1 channel conductance. Invest Ophthalmol Vis Sci 49:3134-42 |
| Shen, Jin-Song; Meng, Xing-Li; Moore, David F et al. (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95:163-8 |
| Shen, Jin-Song; Edwards, Nancy J; Hong, Young Bin et al. (2008) Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem Biophys Res Commun 369:1071-5 |
| Shin, Sang-Hoon; Murray, Gary J; Kluepfel-Stahl, Stefanie et al. (2007) Screening for pharmacological chaperones in Fabry disease. Biochem Biophys Res Commun 359:168-73 |
| Shen, Jin-Song; Meng, Xing-Li; Schiffmann, Raphael et al. (2007) Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab 92:137-44 |
| Askari, Hasan; Kaneski, Christine R; Semino-Mora, Cristina et al. (2007) Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch 451:823-34 |
| Moore, David F; Kaneski, Christine R; Askari, Hasan et al. (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258-63 |
| Lonser, R R; Schiffman, R; Robison, R A et al. (2007) Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology 68:254-61 |
| Yoshimitsu, M; Higuchi, K; Ramsubir, S et al. (2007) Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther 14:256-65 |
Showing the most recent 10 out of 52 publications
